FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal

Market Intelligence Analysis

AI-Powered
Why This Matters

The FDA has agreed to review Moderna's mRNA flu vaccine application, paving the way for its potential approval and availability for the upcoming influenza season.

Market Impact

Market impact analysis based on bullish sentiment with 90% confidence.

Sentiment
Bullish
AI Confidence
90%
Time Horizon
Short Term

Article Context

Note: This is a brief excerpt for context. Click below to read the full article on the original source.

The FDA is slated to make a decision on the flu shot on Aug. 5, which will allow Moderna to make the vaccine available for the upcoming influenza season.

Continue Reading
Full article on CNBC
Read Full Article
Original article published by CNBC on February 18, 2026.
Analysis and insights provided by AnalystMarkets AI.